Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    DTRA-Backed Multiplex Molecular Flu Diagnostic Gains FDA Approval

    By Global Biodefense StaffNovember 5, 2016
    Influenza Surveillance and Preparedness
    Share
    Facebook LinkedIn Reddit Email

    The Food and Drug Administration (FDA) recently approved the FilmArray® Respiratory Panel EZ detection and diagnosis device for use in non-laboratory environments. Cofunded by the Defense Threat Reduction Agency’s Joint Science and Technology Office and BioFire Diagnostics, this new device rapidly detects and diagnoses illnesses that threaten our warfighters and prevent the spread of disease.

    The RP EZ diagnostic test requires only minutes for medical personnel to administer and can detect 11 viral and 3 bacterial pathogens associated with respiratory infections within an hour. To date, approximately 3,000 FilmArray RP EZ® units are in service globally.

    Managed by DTRA’s Dr. Nathan Adams, this milestone marks the first time a highly multiplexed molecular diagnostic test was granted the FDA’s Clinical Laboratory Improvement Amendments (CLIA)-waiver. The CLIA waiver allows testing of the device by everyday users, such as doctor’s offices and clinics.

    This milestone provides the Department of Defense and health workers with real-time force protection capabilities to detect and diagnose diseases that cause public health concerns such as influenza, the common cold or whooping cough.

    “The FilmArray® RP EZ device is an important part of a suite of detection and diagnosis tools currently under development for the protection of our troops. The sure-fire device allows for quicker medical care for deployed warfighters, especially those on ships or in areas without access to more definitive care,” said Dr. Ronald Hann, director for DTRA’s Joint Science and Technology Office.

    FilmArray® RP EZ clinical trials were supported by the U.S. Department of Defense Chemical and Biological Defense program through DTRA. Trial sites included primary care, pediatric, community, and family practice clinics. A mix of adult and pediatric subjects with signs or symptoms of respiratory infection were eligible to participate in the study. Operators in the CLIA-waived setting, comprised primarily of nurses and medical assistants, achieved highly accurate results with overall 96.8% positive agreement and 99.5% negative agreement with an FDA-cleared molecular comparative method.

    Defense Threat Reduction Agency Influenza RSV
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleZalgen and NOWDx Collaborate on Rapid Diagnostics for Ebola, Tropical Diseases
    Next Article Nobel Prize Winner Part of Chem-Bio Defense Research Portfolio

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Terrorism and the Pandemic: Weaponizing a Public Health Crisis

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    Healthcare Workers Express Outrage at Flawed CDC Mask Guidance

    September 18, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.